Creative Enzymes, a global enzyme technology service provider, has launched an AI-integrated platform designed to accelerate the development of enzyme catalysts for industrial biomanufacturing. The platform addresses a critical gap between identifying biocatalysis opportunities and having suitable enzymes available, a bottleneck that traditional methods struggle to overcome. By merging computational enzyme engineering with practical process development, the platform delivers AI-Driven Biocatalysis Solutions that are both predictable in silico and stable at industrial scale.
AI brings critical value by predicting enzyme candidates best suited for specific reactions, designing enzymes constrained by process parameters rather than biological factors, and leveraging molecular features to anticipate process performance in advance. This reduces the need for extensive experimental testing, saving R&D costs and lowering the risk of process failure. The platform also opens routes to molecules previously inaccessible to enzymatic conversion, enabling new product opportunities.
The platform's capabilities are delivered through three specialized service modules. The end-to-end AI-driven solution for biocatalyst discovery and engineering spans target reaction analysis to scale-up characterization, including computational screening, process optimization, and scale-up evaluation. For moderately complex targets, this reduces the design-build-test-learn cycle from 12–24 months to 8–12 months. The AI-Driven Industrial Biocatalysis module focuses on closing the gap between lab-scale and commercial production, addressing substrate concentration optimization, cofactor regeneration, immobilization, and process analytical technology integration. The AI-Driven Green Biocatalysis module provides sustainability-focused solutions, leveraging enzymatic reactions that occur in aqueous media at room temperature, minimizing organic solvents, emissions, and energy use.
A recent case study demonstrated the platform's capabilities in transaminase engineering. Researchers developed a 6D protein engineering framework combining interaction energy, solvent effects, and 1.39 million structural fragments to predict beneficial mutations. Five AI-selected transaminase variants, each with nine mutations, showed high solubility and catalytic stability at 7-liter fermentation scale. The engineered enzymes converted prochiral ketones to sitagliptin with enantiomeric purity exceeding 99% and conversion rates up to 89% during scale-up.
The platform is already making an impact in pharmaceuticals, particularly for asymmetric synthesis of chiral intermediates and replacing hazardous reagents. Agrochemicals and food industries are also adopting AI biocatalysis to fine-tune toxicology profiles and deliver cleaner labels, while fine chemicals and personal care sectors explore high-value conversions and sustainable processes.
